Introduktion
Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Alexander J Denner. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.
Gennemsnitlig handelsrentabilitet
Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.
Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.
Opdateringsfrekvens: Dagligt
Virksomheder med rapporterede insider-stillinger
SEC-registreringen viser, at Alexander J Denner har rapporteret besiddelser eller handler i følgende virksomheder:
Sikkerhed | Titel | Senest indberettede beholdninger |
---|---|---|
US:IRWD / Ironwood Pharmaceuticals, Inc. | Director, 10% Owner | 247.680 |
US:INVA / Innoviva, Inc. | 10% Owner | 5.658.705 |
US:BIIB / Biogen Inc. | Director | 15.099 |
US:ITRM / Iterum Therapeutics plc | 10% Owner | 0 |
US:SRSA / Sarissa Capital Acquisition Corp - Class A | 10% Owner | 5.000.000 |
US:MDCO / Medicines Company | Director | 0 |
US:RGLS / Regulus Therapeutics Inc. | 10% Owner | 6.083.471 |
US:APRI / Apricus Biosciences, Inc. | 10% Owner | 653.409 |
US:BIVV / Bioverativ Inc. | Director | 0 |
US:ARIA / ARIAD Pharmaceuticals, Inc. | Director | 0 |
US:928551AA8 / VIVUS, Inc. Bond | Director | 25.000 |
US:ENZN / Enzon Pharmaceuticals, Inc. | Director | 40.258 |
US:AMLN / Amylin Pharmaceuticals Inc | Director | 0 |
Sådan fortolkes diagrammerne
Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Alexander J Denner. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.
I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.
Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.
Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.
Insiderkøb ENZN / Enzon Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ENZN / Enzon Pharmaceuticals, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Maks |
Pris kl Maks |
Maks Fortjeneste ($) |
Maks. afkast (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg ENZN / Enzon Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ENZN / Enzon Pharmaceuticals, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb INVA / Innoviva, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ENZN / Enzon Pharmaceuticals, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg INVA / Innoviva, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ENZN / Enzon Pharmaceuticals, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb IRWD / Ironwood Pharmaceuticals, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ENZN / Enzon Pharmaceuticals, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg IRWD / Ironwood Pharmaceuticals, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ENZN / Enzon Pharmaceuticals, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderkøb SEELQ / Seelos Therapeutics, Inc. – kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ENZN / Enzon Pharmaceuticals, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insidersalg SEELQ / Seelos Therapeutics, Inc. – kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ENZN / Enzon Pharmaceuticals, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Handelsdato | Ticker | Insider | Rapporteret Aktier |
Rapporteret Pris |
Justeret Aktier |
Justeret Pris |
Omkostningsgrundlag | dage til Min |
Pris kl Min |
Max tab Undgået ($) |
Max tab Undgået (%) |
---|---|---|---|---|---|---|---|
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination |
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Insiderhandelshistorie
Denne tabel viser den komplette liste over insiderhandler foretaget af Alexander J Denner som oplyst til Securities Exchange Commission (SEC).
Fil dato | Transdato | Form | Ticker | Sikkerhed | Kode | Aktier | Resterende aktier | Procent Lave om |
Del Pris |
Tran Værdi |
Tilbage Værdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-09-17 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 11.718 | 247.680 | 4,97 | ||||
2025-06-17 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 24.193 | 235.962 | 11,42 | ||||
2025-06-12 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 45.000 | 211.769 | 26,98 | ||||
2025-04-04 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 10.416 | 166.769 | 6,66 | ||||
2025-03-06 |
|
4 | INVA |
Innoviva, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -1.196.746 | 5.658.705 | -17,46 | 17,52 | -20.964.237 | 99.127.497 | |
2025-03-06 |
|
4 | INVA |
Innoviva, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -270.374 | 6.855.451 | -3,79 | 17,63 | -4.766.126 | 120.847.205 | |
2025-03-06 |
|
4 | INVA |
Innoviva, Inc.
Common Stock, par value $0.01 per share |
S - Sale | -151.175 | 7.125.825 | -2,08 | 17,63 | -2.665.079 | 125.621.882 | |
2024-12-18 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 4.249 | 156.353 | 2,79 | ||||
2024-09-18 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 3.282 | 152.104 | 2,21 | ||||
2024-06-21 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 24.311 | 148.822 | 19,53 | ||||
2024-06-18 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 2.572 | 124.511 | 2,11 | ||||
2024-03-19 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 1.662 | 121.939 | 1,38 | ||||
2023-12-19 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 1.347 | 120.277 | 1,13 | ||||
2023-09-19 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 1.798 | 118.930 | 1,54 | ||||
2023-06-22 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 22.350 | 117.132 | 23,58 | ||||
2023-06-20 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 1.359 | 94.782 | 1,45 | ||||
2023-06-20 |
|
4 | INVA |
Innoviva, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 62.000 | 7.277.000 | 0,86 | 13,13 | 814.196 | 95.563.019 | |
2023-06-07 |
|
4 | INVA |
Innoviva, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 8.000 | 7.215.000 | 0,11 | 13,05 | 104.384 | 94.141.320 | |
2023-06-07 |
|
4 | INVA |
Innoviva, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 7.000 | 7.207.000 | 0,10 | 13,04 | 91.297 | 93.996.577 | |
2023-05-30 |
|
4 | INVA |
Innoviva, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 120.000 | 7.200.000 | 1,69 | 13,01 | 1.560.648 | 93.638.880 | |
2023-05-30 |
|
4 | INVA |
Innoviva, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 30.000 | 7.080.000 | 0,43 | 13,12 | 393.729 | 92.920.044 | |
2023-05-30 |
|
4 | INVA |
Innoviva, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 50.000 | 7.050.000 | 0,71 | 13,09 | 654.330 | 92.260.530 | |
2023-05-19 |
|
4 | INVA |
Innoviva, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 10.000 | 6.964.000 | 0,14 | 13,05 | 130.538 | 90.906.663 | |
2023-05-19 |
|
4 | INVA |
Innoviva, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 50.000 | 6.954.000 | 0,72 | 13,07 | 653.690 | 90.915.205 | |
2023-05-19 |
|
4/A | INVA |
Innoviva, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 36.000 | 7.000.000 | 0,52 | 13,48 | 485.147 | 94.334.100 | |
2023-05-19 |
|
4/A | INVA |
Innoviva, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 10.000 | 6.964.000 | 0,14 | 13,05 | 130.538 | 90.906.663 | |
2023-05-19 |
|
4/A | INVA |
Innoviva, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 50.000 | 6.954.000 | 0,72 | 13,07 | 653.690 | 90.915.205 | |
2023-05-15 | 3 | INVA |
Innoviva, Inc.
Common Stock, par value $0.01 per share |
6.614.000 | ||||||||
2023-05-15 |
|
4 | INVA |
Innoviva, Inc.
Common Stock, par value $0.01 per share |
P - Purchase | 290.000 | 6.904.000 | 4,38 | 12,34 | 3.577.411 | 85.167.054 | |
2023-03-17 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 1.438 | 93.423 | 1,56 | ||||
2022-12-19 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 1.244 | 91.985 | 1,37 | ||||
2022-09-19 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 1.374 | 90.741 | 1,54 | ||||
2022-06-17 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 1.222 | 89.367 | 1,39 | ||||
2022-06-17 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
A - Award | 1.370 | 15.099 | 9,98 | ||||
2022-06-03 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 21.571 | 88.145 | 32,40 | ||||
2022-03-17 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 1.152 | 66.574 | 1,76 | ||||
2021-12-17 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 1.211 | 65.422 | 1,89 | ||||
2021-09-17 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 1.137 | 64.211 | 1,80 | ||||
2021-07-02 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
A - Award | 775 | 13.729 | 5,98 | ||||
2021-06-16 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 1.229 | 63.074 | 1,99 | ||||
2021-06-04 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 22.766 | 61.845 | 58,26 | ||||
2021-03-17 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 1.235 | 39.079 | 3,26 | ||||
2021-03-10 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
P - Purchase | 75.000 | 16.390.000 | 0,46 | 10,54 | 790.500 | 172.750.600 | |
2021-03-10 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
P - Purchase | 150.000 | 16.315.000 | 0,93 | 10,30 | 1.545.000 | 168.044.500 | |
2021-03-05 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
P - Purchase | 175.000 | 16.165.000 | 1,09 | 10,01 | 1.751.750 | 161.811.650 | |
2021-03-05 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
P - Purchase | 250.000 | 15.990.000 | 1,59 | 10,00 | 2.500.000 | 159.900.000 | |
2021-03-05 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
P - Purchase | 350.000 | 15.740.000 | 2,27 | 10,02 | 3.507.000 | 157.714.800 | |
2021-03-02 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
P - Purchase | 500.000 | 15.390.000 | 3,36 | 9,56 | 4.780.000 | 147.128.400 | |
2021-03-02 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
P - Purchase | 344.900 | 14.890.000 | 2,37 | 9,60 | 3.311.040 | 142.944.000 | |
2021-03-02 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
P - Purchase | 505.100 | 14.545.100 | 3,60 | 9,20 | 4.646.920 | 133.814.920 | |
2021-02-12 |
|
4 | ITRM |
Iterum Therapeutics plc
Ordinary Shares |
S - Sale | -10.619.949 | 0 | -100,00 | 2,27 | -24.107.284 | ||
2021-02-12 |
|
4 | ITRM |
Iterum Therapeutics plc
6.500% Exchangeable Senior Subordinated Note due 2025 |
C - Conversion | -15.000.000 | 0 | -100,00 | ||||
2021-02-12 |
|
4 | ITRM |
Iterum Therapeutics plc
Ordinary Shares |
S - Sale | -10.000.000 | 10.619.949 | -48,50 | 2,59 | -25.900.000 | 27.505.668 | |
2021-02-12 |
|
4 | ITRM |
Iterum Therapeutics plc
Ordinary Shares |
C - Conversion | 20.619.949 | 20.616.949 | -687.331,63 | ||||
2020-12-17 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 661 | 37.844 | 1,78 | ||||
2020-11-09 | 3 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
14.040.000 | ||||||||
2020-11-09 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 24.925 | 37.183 | 203,34 | ||||
2020-11-09 |
|
4 | IRWD |
IRONWOOD PHARMACEUTICALS INC
Class A Common Stock |
A - Award | 12.258 | 12.258 | |||||
2020-11-03 |
|
4 | SRSA |
Sarissa Capital Acquisition Corp.
Class B ordinary shares |
J - Other | -31.250 | 5.000.000 | -0,62 | ||||
2020-10-23 |
|
4 | SRSA |
Sarissa Capital Acquisition Corp.
Warrants to purchase Class A ordinary shares |
P - Purchase | 3.333.333 | 3.333.333 | 1,50 | 5.000.000 | 5.000.000 | ||
2020-06-05 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
A - Award | 890 | 12.954 | 7,38 | ||||
2020-01-06 |
|
4 | MDCO |
MEDICINES CO /DE
Stock Option |
D - Sale to Issuer | -13.410 | 0 | -100,00 | ||||
2020-01-06 |
|
4 | MDCO |
MEDICINES CO /DE
Stock Option |
D - Sale to Issuer | -9.141 | 0 | -100,00 | ||||
2020-01-06 |
|
4 | MDCO |
MEDICINES CO /DE
Stock Option |
D - Sale to Issuer | -8.577 | 0 | -100,00 | ||||
2020-01-06 |
|
4 | MDCO |
MEDICINES CO /DE
Stock Option |
D - Sale to Issuer | -9.700 | 0 | -100,00 | ||||
2020-01-06 |
|
4 | MDCO |
MEDICINES CO /DE
Stock Option |
D - Sale to Issuer | -27.230 | 0 | -100,00 | ||||
2020-01-06 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
D - Sale to Issuer | -4.202.000 | 0 | -100,00 | ||||
2020-01-06 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
D - Sale to Issuer | -85.813 | 0 | -100,00 | ||||
2020-01-03 |
|
4 | RGLS |
Regulus Therapeutics Inc.
Warrants to Purchase Common Stock |
P - Purchase | 4.231.620 | 6.083.471 | 228,51 | ||||
2020-01-03 |
|
4 | RGLS |
Regulus Therapeutics Inc.
Class A-2 Convertible Preferred Stock |
P - Purchase | 423.162 | 423.162 | |||||
2019-06-28 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
P - Purchase | 50.000 | 4.202.000 | 1,20 | 33,00 | 1.650.000 | 138.666.000 | |
2019-06-20 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
A - Award | 1.155 | 12.064 | 10,59 | ||||
2019-06-03 |
|
4 | MDCO |
MEDICINES CO /DE
Stock Option (right-to-buy) |
A - Award | 13.410 | 13.410 | |||||
2019-06-03 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
A - Award | 3.663 | 14.092 | 35,12 | ||||
2019-05-31 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
P - Purchase | 50.000 | 4.152.000 | 1,22 | 34,81 | 1.740.500 | 144.531.120 | |
2019-05-31 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
P - Purchase | 35.000 | 4.102.000 | 0,86 | 34,85 | 1.219.750 | 142.954.700 | |
2019-05-22 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
P - Purchase | 139.000 | 4.067.000 | 3,54 | 33,13 | 4.605.070 | 134.739.710 | |
2019-05-22 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
P - Purchase | 132.000 | 3.928.000 | 3,48 | 33,95 | 4.481.400 | 133.355.600 | |
2019-05-22 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
P - Purchase | 160.000 | 3.796.000 | 4,40 | 34,50 | 5.520.000 | 130.962.000 | |
2019-05-17 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock |
3.703.702 | ||||||||
2019-05-17 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock |
3.703.702 | ||||||||
2019-05-17 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock |
3.703.702 | ||||||||
2019-05-17 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock |
3.703.702 | ||||||||
2019-05-17 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock |
3.703.702 | ||||||||
2019-05-17 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock |
3.703.702 | ||||||||
2019-05-17 | 3 | RGLS |
Regulus Therapeutics Inc.
Common Stock |
3.703.702 | ||||||||
2019-05-02 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
P - Purchase | 38.000 | 643.000 | 6,28 | 231,24 | 8.787.120 | 148.687.320 | |
2019-05-02 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
P - Purchase | 30.000 | 605.000 | 5,22 | 229,46 | 6.883.800 | 138.823.300 | |
2019-05-02 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
P - Purchase | 50.342 | 575.000 | 9,60 | 229,25 | 11.540.904 | 131.818.750 | |
2019-03-08 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
P - Purchase | 248.100 | 3.636.000 | 7,32 | 24,91 | 6.180.171 | 90.572.760 | |
2019-03-05 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
P - Purchase | 181.900 | 3.387.900 | 5,67 | 26,07 | 4.742.133 | 88.322.553 | |
2019-03-05 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
P - Purchase | 325.000 | 3.206.000 | 11,28 | 25,45 | 8.271.250 | 81.592.700 | |
2019-03-05 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
P - Purchase | 100.000 | 2.881.000 | 3,60 | 25,15 | 2.515.000 | 72.457.150 | |
2019-02-01 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
P - Purchase | 7.000 | 524.658 | 1,35 | 328,45 | 2.299.163 | 172.324.864 | |
2019-02-01 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
P - Purchase | 25.800 | 517.658 | 5,25 | 330,52 | 8.527.393 | 171.095.856 | |
2019-02-01 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
P - Purchase | 30.000 | 491.858 | 6,50 | 324,86 | 9.745.851 | 159.785.826 | |
2018-12-21 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
P - Purchase | 10.000 | 2.781.000 | 0,36 | 17,89 | 178.900 | 49.752.090 | |
2018-12-18 |
|
4 | MDCO |
MEDICINES CO /DE
3.50% Convertible Senior Notes due 2024 |
P - Purchase | 20.000.000,00 | ||||||
2018-12-18 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
P - Purchase | 10.000 | 2.771.000 | 0,36 | 18,18 | 181.800 | 50.376.780 | |
2018-12-18 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
P - Purchase | 20.000 | 2.761.000 | 0,73 | 17,91 | 358.200 | 49.449.510 | |
2018-12-17 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
P - Purchase | 219.000 | 2.741.000 | 8,68 | 18,97 | 4.154.430 | 51.996.770 | |
2018-12-17 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
P - Purchase | 600.000 | 2.522.000 | 31,22 | 20,73 | 12.438.000 | 52.281.060 | |
2018-06-14 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
A - Award | 880 | 10.909 | 8,77 | ||||
2018-06-04 |
|
4 | MDCO |
MEDICINES CO /DE
Stock Option (right-to-buy) |
A - Award | 9.141 | 9.141 | |||||
2018-06-04 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
A - Award | 3.766 | 10.429 | 56,52 | ||||
2018-04-27 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
P - Purchase | 48.000 | 461.858 | 11,60 | 269,91 | 12.955.680 | 124.660.093 | |
2018-03-23 |
|
4 | APRI |
APRICUS BIOSCIENCES, INC.
Warrants to Purchase Common Stock |
J - Other | 653.409 | 653.409 | |||||
2018-03-23 |
|
4 | APRI |
APRICUS BIOSCIENCES, INC.
Warrants to Purchase Common Stock |
J - Other | -653.409 | 0 | -100,00 | ||||
2018-03-08 |
|
4 | BIVV |
Bioverativ Inc.
Non-Qualified Stock Option |
D - Sale to Issuer | -26.818 | 0 | -100,00 | ||||
2018-03-08 |
|
4 | BIVV |
Bioverativ Inc.
Restricted Stock Units |
D - Sale to Issuer | -5.455 | 0 | -100,00 | ||||
2018-03-08 |
|
4 | BIVV |
Bioverativ Inc.
Common Stock |
D - Sale to Issuer | -1.165.000 | 0 | -100,00 | ||||
2018-03-08 |
|
4 | BIVV |
Bioverativ Inc.
Common Stock |
D - Sale to Issuer | -5.001 | 0 | -100,00 | ||||
2018-02-02 |
|
4 | BIVV |
Bioverativ Inc.
Restricted Stock Units |
A - Award | 5.455 | 5.455 | |||||
2017-11-30 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
P - Purchase | 170.000 | 1.922.000 | 9,70 | 30,03 | 5.105.100 | 57.717.660 | |
2017-11-30 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
P - Purchase | 10.000 | 413.858 | 2,48 | 319,84 | 3.198.400 | 132.368.343 | |
2017-11-30 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
P - Purchase | 20.000 | 403.858 | 5,21 | 316,12 | 6.322.400 | 127.667.591 | |
2017-09-01 |
|
4 | APRI |
APRICUS BIOSCIENCES, INC.
Warrants to purchase Common Stock |
P - Purchase | 2.835 | 672.453 | 0,42 | ||||
2017-09-01 |
|
4 | APRI |
APRICUS BIOSCIENCES, INC.
Common Stock |
P - Purchase | 6.104 | 1.447.906 | 0,42 | 1,63 | 9.950 | 2.360.087 | |
2017-08-31 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
A - Award | 7.146 | 1.752.000 | 0,41 | 36,69 | 262.187 | 64.280.880 | |
2017-08-31 |
|
4 | BIVV |
Bioverativ Inc.
Common Stock |
A - Award | 932 | 1.165.000 | 0,08 | 56,69 | 52.835 | 66.043.850 | |
2017-08-31 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
A - Award | 933 | 383.858 | 0,24 | 316,56 | 295.350 | 121.514.088 | |
2017-06-09 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
A - Award | 1.055 | 10.029 | 11,76 | ||||
2017-06-01 |
|
4 | BIVV |
Bioverativ Inc.
Common Stock |
P - Purchase | 90.000 | 1.165.000 | 8,37 | 55,93 | 5.033.475 | 65.155.538 | |
2017-05-30 |
|
4 | MDCO |
MEDICINES CO /DE
Stock Option (right-to-buy |
A - Award | 8.577 | 8.577 | |||||
2017-05-30 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
A - Award | 3.237 | 6.663 | 94,48 | ||||
2017-05-26 |
|
4 | BIVV |
Bioverativ Inc.
Common Stock |
P - Purchase | 450.000 | 1.075.000 | 72,00 | 57,21 | 25.745.130 | 61.502.255 | |
2017-05-26 |
|
4 | BIVV |
Bioverativ Inc.
Common Stock |
P - Purchase | 130.000 | 625.000 | 26,26 | 54,98 | 7.147.907 | 34.364.938 | |
2017-05-26 |
|
4 | BIVV |
Bioverativ Inc.
Common Stock |
P - Purchase | 340.000 | 495.000 | 219,35 | 54,16 | 18.414.400 | 26.809.200 | |
2017-05-01 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
P - Purchase | 58.858 | 383.858 | 18,11 | 278,48 | 16.390.776 | 106.896.776 | |
2017-05-01 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
P - Purchase | 15.000 | 325.000 | 4,84 | 278,58 | 4.178.700 | 90.538.500 | |
2017-04-17 |
|
4 | BIVV |
Bioverativ Inc.
Common Stock |
A - Award | 1.056 | 5.001 | 26,77 | 56,83 | 60.012 | 284.207 | |
2017-03-27 |
|
4/A | BIVV |
Bioverativ Inc.
Non-Qualified Stock Option |
A - Award | 26.818 | 26.818 | |||||
2017-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
3.625% Convertible Notes due 2019 |
D - Sale to Issuer | -3.459.280 | 0 | -100,00 | ||||
2017-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
3.625% Convertible Notes due 2019 |
D - Sale to Issuer | -5.340.720 | 0 | -100,00 | ||||
2017-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -25.000 | 0 | -100,00 | ||||
2017-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -25.000 | 0 | -100,00 | ||||
2017-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -25.000 | 0 | -100,00 | ||||
2017-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | -75.000 | 0 | -100,00 | ||||
2017-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -5.051.335 | 0 | -100,00 | ||||
2017-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -7.798.665 | 0 | -100,00 | ||||
2017-02-16 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
D - Sale to Issuer | -53.173 | 0 | -100,00 | ||||
2017-02-16 |
|
4 | BIVV |
Bioverativ Inc.
Non-Qualified Stock Option |
A - Award | 26.770 | 26.770 | |||||
2017-02-02 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Employee Stock Option (Right to Buy) |
A - Award | 25.000 | 25.000 | 23,82 | 595.500 | 595.500 | ||
2017-02-02 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
A - Award | 12.500 | 53.173 | 30,73 | ||||
2017-02-02 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
A - Award | 5.508 | 40.673 | 15,66 | ||||
2017-01-19 | 3 | BIVV |
Bioverativ Inc.
Common Stock |
0 | ||||||||
2016-06-09 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
A - Award | 1.060 | 8.950 | 13,43 | ||||
2016-05-31 |
|
4 | MDCO |
MEDICINES CO /DE
Stock Option (right-to-buy) |
A - Award | 9.700 | 9.700 | |||||
2016-05-31 |
|
4 | MDCO |
MEDICINES CO /DE
Common Stock |
A - Award | 3.426 | 3.426 | |||||
2016-03-07 |
|
4 | APRI |
APRICUS BIOSCIENCES, INC.
Warrants to Purchase Common Stock |
P - Purchase | 3.323.864 | 6.724.525 | 97,74 | ||||
2016-03-07 |
|
4 | APRI |
APRICUS BIOSCIENCES, INC.
Common Stock |
P - Purchase | 6.647.728 | 14.479.053 | 84,89 | 0,88 | 5.850.001 | 12.741.567 | |
2016-02-04 |
|
4 | MDCO |
MEDICINES CO /DE
Call Option (right-to-buy) |
A - Award | 27.230 | 27.230 | |||||
2016-02-04 | 3 | MDCO |
MEDICINES CO /DE
Common Stock |
2.410.595 | ||||||||
2016-02-04 | 3 | MDCO |
MEDICINES CO /DE
Common Stock |
2.845.405 | ||||||||
2016-02-04 | 3 | MDCO |
MEDICINES CO /DE
Common Stock |
2.410.595 | ||||||||
2016-02-04 | 3 | MDCO |
MEDICINES CO /DE
Common Stock |
2.845.405 | ||||||||
2016-02-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 25.000 | 25.000 | 4,91 | 122.750 | 122.750 | ||
2016-02-03 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
A - Award | 12.500 | 35.165 | 55,15 | ||||
2016-01-14 |
|
4 | APRI |
APRICUS BIOSCIENCES, INC.
Warrants to Purchase Common Stock |
P - Purchase | 653.409 | 3.400.661 | 23,78 | ||||
2016-01-14 |
|
4 | APRI |
APRICUS BIOSCIENCES, INC.
Common Stock |
P - Purchase | 1.306.819 | 7.831.324 | 20,03 | 0,88 | 1.150.001 | 6.891.565 | |
2015-11-03 |
|
4 | VVUS |
VIVUS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 25.000 | 25.000 | |||||
2015-10-26 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
P - Purchase | 100.000 | 310.000 | 47,62 | 276,77 | 27.677.000 | 85.798.700 | |
2015-10-26 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
P - Purchase | 210.000 | 210.000 | 277,80 | 58.338.000 | 58.338.000 | ||
2015-06-11 |
|
4 | BIIB |
BIOGEN INC.
Common Stock |
A - Award | 695 | 7.890 | 9,66 | ||||
2015-05-29 |
|
4 | VVUS |
VIVUS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 25.000 | 25.000 | |||||
2015-02-23 | 3 | APRI |
APRICUS BIOSCIENCES, INC.
Common Stock |
13.049.010 | ||||||||
2015-02-23 | 3 | APRI |
APRICUS BIOSCIENCES, INC.
Common Stock |
13.049.010 | ||||||||
2015-02-23 | 3 | APRI |
APRICUS BIOSCIENCES, INC.
Common Stock |
13.049.010 | ||||||||
2015-02-23 | 3 | APRI |
APRICUS BIOSCIENCES, INC.
Common Stock |
13.049.010 | ||||||||
2015-02-04 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 25.000 | 25.000 | 6,45 | 161.250 | 161.250 | ||
2015-02-04 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
A - Award | 22.665 | 22.665 | |||||
2014-08-19 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
3.625% Convertible Notes due 2019 |
P - Purchase | 3.459.280 | 3.459.280 | 3.256.047,00 | 11.263.578.266.160 | 11.263.578.266.160 | ||
2014-08-19 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
3.625% Convertible Notes due 2019 |
P - Purchase | 5.340.720 | 5.340.720 | 5.026.953,00 | 26.847.548.426.160 | 26.847.548.426.160 | ||
2014-08-19 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
P - Purchase | 234.534 | 5.051.335 | 4,87 | 5,83 | 1.367.333 | 29.449.283 | |
2014-08-19 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
P - Purchase | 615.466 | 7.798.665 | 8,57 | 5,83 | 3.588.167 | 45.466.217 | |
2014-06-16 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
A - Award | 870 | 7.195 | 13,75 | ||||
2014-02-24 |
|
4 | ARIA |
ARIAD PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 75.000 | 75.000 | |||||
2014-02-24 | 3 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
16.816.801 | ||||||||
2014-02-24 | 3 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
19.183.199 | ||||||||
2014-02-24 | 3 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
16.816.801 | ||||||||
2014-02-24 | 3 | ARIA |
ARIAD PHARMACEUTICALS INC
Common Stock |
19.183.199 | ||||||||
2013-11-12 |
|
4 | VVUS |
VIVUS INC
Common Stock |
P - Purchase | 149.776 | 2.573.943 | 6,18 | 8,78 | 1.315.033 | 22.599.220 | |
2013-11-12 |
|
4 | VVUS |
VIVUS INC
Common Stock |
P - Purchase | 417.068 | 2.424.167 | 20,78 | 8,52 | 3.553.419 | 20.653.903 | |
2013-08-16 |
|
4 | VVUS |
VIVUS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 25.000 | 25.000 | |||||
2013-06-17 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | -2.900 | 6.325 | -31,44 | 212,00 | -614.800 | 1.340.900 |
2013-06-13 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
A - Award | 1.305 | 9.225 | 16,48 | ||||
2013-06-03 | 3 | VVUS |
VIVUS INC
Common Stock, par value $0.001 |
2.007.099 | ||||||||
2013-05-31 |
|
4 | BIIB |
BIOGEN IDEC INC.
Stock Option (Right to Buy) |
M - Exercise | X | -3.000 | 0 | -100,00 | |||
2013-05-31 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
M - Exercise | X | 3.000 | 7.920 | 60,98 | 53,43 | 160.290 | 423.166 |
2013-05-29 |
|
4 | BIIB |
BIOGEN IDEC INC.
Stock Option (Right to Buy) |
M - Exercise | X | -2.975 | 3.000 | -49,79 | |||
2013-05-29 |
|
4 | BIIB |
BIOGEN IDEC INC.
Stock Option (Right to Buy) |
M - Exercise | X | -35.000 | 0 | -100,00 | |||
2013-05-29 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | -1.175 | 4.920 | -19,28 | 239,85 | -281.828 | 1.180.082 |
2013-05-29 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | -1.500 | 6.095 | -19,75 | 238,87 | -358.311 | 1.455.937 |
2013-05-29 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | -300 | 7.595 | -3,80 | 237,38 | -71.214 | 1.802.901 |
2013-05-29 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
M - Exercise | X | 2.975 | 7.895 | 60,47 | 53,43 | 158.954 | 421.830 |
2013-05-29 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | -906 | 4.920 | -15,55 | 242,40 | -219.616 | 1.192.618 |
2013-05-29 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | -12.094 | 5.826 | -67,49 | 241,92 | -2.925.756 | 1.409.414 |
2013-05-29 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | -7.500 | 17.920 | -29,50 | 240,75 | -1.805.602 | 4.314.186 |
2013-05-29 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | -11.300 | 25.420 | -30,77 | 239,95 | -2.711.458 | 6.099.580 |
2013-05-29 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | -900 | 36.720 | -2,39 | 239,04 | -215.137 | 8.777.586 |
2013-05-29 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | -2.300 | 37.620 | -5,76 | 237,73 | -546.774 | 8.943.327 |
2013-05-29 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
M - Exercise | X | 35.000 | 39.920 | 711,38 | 53,43 | 1.870.050 | 2.132.926 |
2013-01-04 |
|
4 | ENZN |
ENZON PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 40.258 | 40.258 | |||||
2012-12-28 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | -1.300 | 4.920 | -20,90 | 149,04 | -193.758 | 733.301 |
2012-12-28 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | -2.691 | 6.220 | -30,20 | 148,02 | -398.327 | 920.697 |
2012-12-28 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
S - Sale | X | -3.989 | 8.911 | -30,92 | 148,89 | -593.914 | 1.326.741 |
2012-08-10 |
|
4 | AMLN |
AMYLIN PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
J - Other | -20.000 | 0 | -100,00 | 31,00 | -620.000 | ||
2012-08-10 |
|
4 | AMLN |
AMYLIN PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
J - Other | -20.000 | 0 | -100,00 | 31,00 | -620.000 | ||
2012-08-10 |
|
4 | AMLN |
AMYLIN PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
J - Other | -20.000 | 0 | -100,00 | 31,00 | -620.000 | ||
2012-08-10 |
|
4 | AMLN |
AMYLIN PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
J - Other | -30.000 | 0 | -100,00 | 31,00 | -930.000 | ||
2012-08-10 |
|
4 | AMLN |
AMYLIN PHARMACEUTICALS INC
Common Stock |
J - Other | -1.104 | 0 | -100,00 | 31,00 | -34.230 | ||
2012-08-10 |
|
4 | AMLN |
AMYLIN PHARMACEUTICALS INC
Common Stock |
J - Other | -9.057 | 1.104 | -89,13 | 31,00 | -280.761 | 34.230 | |
2012-07-03 |
|
4 | ENZN |
ENZON PHARMACEUTICALS INC
Common Stock |
A - Award | 21.338 | 60.620 | 54,32 | ||||
2012-06-11 |
|
4 | BIIB |
BIOGEN IDEC INC.
Common Stock |
A - Award | 2.020 | 12.900 | 18,57 | ||||
2012-05-17 |
|
4 | AMLN |
AMYLIN PHARMACEUTICALS INC
Non-Qualified Stock Option (right to buy) |
A - Award | 20.000 | 20.000 | |||||
2012-05-17 |
|
4 | AMLN |
AMYLIN PHARMACEUTICALS INC
Common Stock |
A - Award | 3.000 | 10.161 | 41,89 | ||||
2012-01-19 |
|
4 | AMLN |
AMYLIN PHARMACEUTICALS INC
Phantom Stock-Deferred Compensation |
M - Exercise | -1.104 | 0 | -100,00 | ||||
2012-01-19 |
|
4 | AMLN |
AMYLIN PHARMACEUTICALS INC
Phantom Stock-Deferred Compensation |
M - Exercise | -4.889 | 1.104 | -81,58 | ||||
2012-01-19 |
|
4 | AMLN |
AMYLIN PHARMACEUTICALS INC
Common Stock |
S - Sale | -1.832 | 7.161 | -20,37 | 11,59 | -21.238 | 82.996 | |
2012-01-19 |
|
4 | AMLN |
AMYLIN PHARMACEUTICALS INC
Common Stock |
M - Exercise | 1.104 | 8.993 | 14,00 | ||||
2012-01-19 |
|
4 | AMLN |
AMYLIN PHARMACEUTICALS INC
Common Stock |
M - Exercise | 4.889 | 7.889 | 162,97 | ||||
2012-01-05 |
|
4 | ENZN |
ENZON PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 21.988 | 21.988 | |||||
2010-07-06 |
|
4 | ENZN |
ENZON PHARMACEUTICALS INC
Common Stock |
A - Award | 14.086 | 24.518 | 135,03 |